Celestial Biolabs
CELESTIAL NSE
Celestial Biolabs
HealthcareNSE: CELESTIAL Pharmaceuticals & Biotechnology
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
4- Company has low interest coverage ratio.
- Contingent liabilities of Rs.1.29 Cr.
- Company might be capitalizing the interest cost
- Company has high debtors of 7,966 days.
Growth Rate
Revenue Growth
-26%
Net Income Growth
33%
Quarterly Results
| Particulars | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.06 | 0.06 | 0.04 | 0.03 | 0.04 | 0.02 | 0.04 | 0.04 |
| Expenses | 0.33 | 0.15 | 0.11 | 0.18 | 0.27 | 0.11 | 0.07 | 0.07 |
| Operating Profit | -0.27 | -0.09 | -0.07 | -0.15 | -0.23 | -0.09 | -0.03 | -0.03 |
| OPM % | -450% | -150% | -175% | -500% | -575% | -450% | -75% | -75% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 |
| Depreciation | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| PBT | -0.28 | -0.1 | -0.08 | -0.16 | -0.25 | -0.1 | -0.04 | -0.04 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -0.28 | -0.1 | -0.08 | -0.15 | -0.24 | -0.1 | -0.03 | -0.04 |
| EPS in Rs | -0.12 | -0.04 | -0.04 | -0.07 | -0.11 | -0.04 | -0.01 | -0.02 |
Profit & Loss
| Particulars | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|
| Sales | 0.15 | 0.17 | 0.14 |
| Expenses | 0.49 | 0.71 | 0.52 |
| Operating Profit | -0.34 | -0.54 | -0.38 |
| OPM % | -226.67% | -317.65% | -271.43% |
| Other Income | 0 | 0 | 0 |
| Interest | 0.04 | 0.01 | 0.01 |
| Depreciation | 0.03 | 0.03 | 0.04 |
| PBT | -0.41 | -0.58 | -0.43 |
| Tax % | 0% | 0% | — |
| Net Profit | -0.41 | -0.58 | -0.41 |
| EPS in Rs | -0.18 | -0.26 | -0.18 |
| Div. Payout % | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2022 | Mar 2023 | Sep 2023 |
|---|---|---|---|
| Equity Capital | 22.59 | 22.59 | 22.59 |
| Reserves | -19.24 | -19.81 | -19.94 |
| Borrowings | 11.54 | 12.03 | 12.04 |
| Other Liabilities | 2.29 | 2.43 | 2.49 |
| Total Liabilities | 17.18 | 17.24 | 17.18 |
| Fixed Assets | 0.1 | 0.08 | 0.06 |
| CWIP | 12.82 | 12.82 | 12.82 |
| Investments | 0 | 0 | 0 |
| Other Assets | 4.26 | 4.34 | 4.3 |
| Total Assets | 17.18 | 17.24 | 17.18 |
Cash Flow
| Particulars | Mar 2022 | Mar 2023 |
|---|---|---|
| Operating | -0.28 | -0.36 |
| Investing | 0 | 0 |
| Financing | 0.26 | 0.38 |
| Net Cash Flow | -0.02 | 0.02 |
| Free Cash Flow | -0.28 | -0.37 |
| CFO/OP | 82 | 67 |
Ratios
| Particulars | Mar 2022 | Mar 2023 |
|---|---|---|
| Debtor Days | 9,320 | 7,966 |
| Inventory Days | 86.9 | 99.55 |
| Days Payable | 452 | 1,161 |
| Cash Conversion Cycle | 8,955 | 6,904 |
| Working Capital Days | -2,628 | -2,512 |
| ROCE % | — | -3.84% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Celestial Biolabs insights
54 extracted metrics + investor summaries across FY09–FY23.
Documents
1
Clarification On Price Movement
24 Feb - No undisclosed information; attributes price movement to market forces; confirms Listing Regulations compliance. 24 Feb - No undisclosed information; attributes price movement to market forces; confirms Listing Regulations compliance.
2
Clarification sought from VL E-Governance & IT Solutions Ltd
9h - Exchange has sought clarification from VL E-Governance & IT Solutions Ltd on February 23, 2026 with reference to significant movement in price, in order to … 9h - Exchange has sought clarification from VL E-Governance & IT Solutions Ltd on February 23, 2026 with reference to significant movement in price, in order to …
3
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
12 Feb - CARE report: Rs.630cr issue; Rs.400.99cr subscribed; Rs.114.31cr received; undersubscription and sharp share-price decline noted (Dec 31, 2025). 12 Feb - CARE report: Rs.630cr issue; Rs.400.99cr subscribed; Rs.114.31cr received; undersubscription and sharp share-price decline noted (Dec 31, 2025).
4
Results Performance Update Presentation - Q3 FY 2025-26 Results Update
9 Feb - Q3 loss with revenue down 70.5% QoQ; MoU for ₹800 crore Sankalp EPC; proposed 40% HETL acquisition. 9 Feb - Q3 loss with revenue down 70.5% QoQ; MoU for ₹800 crore Sankalp EPC; proposed 40% HETL acquisition.
5
Board Meeting Outcome for VL E Governance & IT Solutions Limited Has informed Regarding Outcome Of Board Meeting Held On February 07, 2026.
7 Feb - Approved Q3/9M FY2025-26 unaudited results (31 Dec 2025); Q3 revenue ₹448.00L; appointed K J Kabra & Associates. 7 Feb - Approved Q3/9M FY2025-26 unaudited results (31 Dec 2025); Q3 revenue ₹448.00L; appointed K J Kabra & Associates.
Frequently Asked Questions about Celestial Biolabs
What does Celestial Biolabs Ltd do?
Celestial Biolabs is engaged in activities of manufacturingof Ayurvedic products and Trading of Feed suppliments.
Where is Celestial Biolabs Ltd (CELESTIAL) listed?
Celestial Biolabs Ltd trades as CELESTIAL on the NSE.
Which sector does Celestial Biolabs Ltd belong to?
Celestial Biolabs Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
Company Information
Celestial Biolabs is engaged in activities of manufacturingof Ayurvedic products and Trading of Feed suppliments.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CELESTIAL.md for Celestial Biolabs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.